Stockreport

Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy' [Seeking Alpha]

Silence Therapeutics Plc - American Depository Share  (SLN) 
PDF Summary Silence Therapeutics focuses on RNA interference therapies, with its lead candidates targeting cardiovascular and hematological diseases via the mRNAi GOLD pl [Read more]